Related Experiment Video
Updated: Sep 27, 2026
Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
Methotrexate for cervical pregnancy. A case report
Cetin Celik1, Ayfer Bala, Ali Acar
1Department of Obstetrics and Gynecology, Selçuk University Faculty of Medicine, Akyokuş, 42080 Konya, Turkey. celikcet@hotmail.com
Background:
The incidence of cervical pregnancy is 1:1,000-95,000 pregnancies and represents < 1% of all ectopic pregnancies. Evacuation of the pregnancy by curettage does not always stop the bleeding because there is little contractile muscle in the cervix. If there is uncontrollable bleeding, hysterectomy is necessary. In selected cases, nonsurgical management offers high success rates. Among medical treatments, the most common is systemic or local administration of methotrexate.
Case:
A 36-year-old woman, gravida 2, para 2, presented with vaginal bleeding and subacute pain in the lower abdomen. The patient was 7 weeks' pregnant according to her last menstrual period. Transvaginal ultrasonography showed a gestational sac of approximately 5 weeks' gestational age implanted in the wall of the cervix. Fifty milligrams of methotrexate was injected into the gestational sac and another 50 mg administered intramuscularly. The hCG level decreased continuously and was no longer detectable after 35 days.
Conclusion:
The use of methotrexate for cervical pregnancy is safe and effective and preserves fertility.
